174 related articles for article (PubMed ID: 22947131)
1. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults.
Delvadia R; Hindle M; Longest PW; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):138-44. PubMed ID: 22947131
[TBL] [Abstract][Full Text] [Related]
2.
Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
[No Abstract] [Full Text] [Related]
3. An Exploration of Factors Affecting
Ruzycki CA; Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
[No Abstract] [Full Text] [Related]
4. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
Delvadia RR; Longest PW; Hindle M; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
[TBL] [Abstract][Full Text] [Related]
5. In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans.
Delvadia RR; Longest PW; Byron PR
J Aerosol Med Pulm Drug Deliv; 2012 Feb; 25(1):32-40. PubMed ID: 22070526
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
Mohan M; Lee S; Guo C; Peri SP; Doub WH
AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
[TBL] [Abstract][Full Text] [Related]
8. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®).
Jiang L; Tang Y; Zhang H; Lu X; Chen X; Zhu J
J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):265-79. PubMed ID: 22280548
[TBL] [Abstract][Full Text] [Related]
9. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
10. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
[TBL] [Abstract][Full Text] [Related]
11. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
[TBL] [Abstract][Full Text] [Related]
12. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
Olsson B; Borgström L; Lundbäck H; Svensson M
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
[TBL] [Abstract][Full Text] [Related]
14. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
[TBL] [Abstract][Full Text] [Related]
15. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.
Tian G; Hindle M; Lee S; Longest PW
Pharm Res; 2015 Oct; 32(10):3170-87. PubMed ID: 25944585
[TBL] [Abstract][Full Text] [Related]
16. Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model.
Below A; Bickmann D; Breitkreutz J
Int J Pharm; 2013 Feb; 444(1-2):169-74. PubMed ID: 23333708
[TBL] [Abstract][Full Text] [Related]
17. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Lipworth BJ; Clark DJ
Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
[TBL] [Abstract][Full Text] [Related]
18. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
19. Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers.
Tavernini S; Farina DJ; Martin AR; Finlay WH
Pharm Res; 2021 Sep; 38(9):1601-1613. PubMed ID: 34463937
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary drug delivery by powder aerosols.
Yang MY; Chan JG; Chan HK
J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
